0001193125-17-358985.txt : 20171201 0001193125-17-358985.hdr.sgml : 20171201 20171201163355 ACCESSION NUMBER: 0001193125-17-358985 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171127 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20171201 DATE AS OF CHANGE: 20171201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 171234544 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 8-K 1 d500209d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 27, 2017

 

 

ALDEYRA THERAPEUTICS, INC.

(Exact name of Registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of incorporation)

 

001-36332   20-1968197
(Commission File No.)   (IRS Employer Identification No.)

131 Hartwell Avenue, Suite 320

Lexington, MA 02421

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (781) 761-4904

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

On November 27, 2017, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) entered into a First Amendment to Lease (the “First Amendment”) with WLC Three VI, L.L.C. (“WLC”) concerning the Company’s corporate headquarters in Lexington, Massachusetts. The First Amendment increases the rentable square footage by 2,427 square feet to 9,351 square feet (the “Phase III Premises”) commencing on or about February 1, 2018 (the “Phase III Commencement Date”). The term with respect to the Phase III Premises shall be for a period ending on December 31, 2020, or as extended under the Company’s option to extend. In accordance with the terms of the First Amendment, the Company’s base rent shall increase on the Phase III Commencement Date to approximately $219,748.50, subject to annual increases over the term of the lease, and excluding the Company’s pro rata share of certain real property taxes, operating expenses, common area maintenance expenses and allowances for tenant improvements. The First Amendment does not change any other material terms of the lease.

The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by the full text of the First Amendment, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the fiscal period ending December 31, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ALDEYRA THERAPEUTICS, INC.

By:

  

/s/ Todd C. Brady, M.D., Ph.D.

  Name: Todd C. Brady, M.D., Ph.D.
  Title: President and Chief Executive Officer

Dated: December 1, 2017